Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic

JAMA Netw Open. 2020 Jul 1;3(7):e2015100. doi: 10.1001/jamanetworkopen.2020.15100.

Abstract

This systematic review examines current randomized clinical trials of therapeutic agents to treat coronavirus disease 2019 (COVID-19).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antimalarials / therapeutic use
  • Antiviral Agents / therapeutic use
  • Azithromycin / therapeutic use
  • Betacoronavirus / isolation & purification
  • Biological Products / therapeutic use
  • COVID-19
  • COVID-19 Serotherapy
  • Chloroquine / therapeutic use*
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / mortality
  • Coronavirus Infections / therapy*
  • Coronavirus Infections / virology
  • Humans
  • Hydroxychloroquine / therapeutic use*
  • Immunization, Passive / methods
  • Non-Randomized Controlled Trials as Topic
  • Pandemics
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / therapy*
  • Pneumonia, Viral / virology
  • Protease Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Randomized Controlled Trials as Topic
  • Respiration, Artificial / methods
  • SARS-CoV-2
  • Viral Load / drug effects

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Antimalarials
  • Antiviral Agents
  • Biological Products
  • Protease Inhibitors
  • remdesivir
  • Adenosine Monophosphate
  • Hydroxychloroquine
  • Azithromycin
  • Chloroquine
  • Protein-Tyrosine Kinases
  • tocilizumab
  • Alanine